On August 24, 2012, Shepherd, Finkelman, Miller & Shah, LLP and its co-counsel filed a Class Action Complaint (“Complaint”) in the U.S. District Court for the Eastern District of Pennsylvania on behalf of their client, Fraternal Order of Police Miami Lodge 20, Insurance Trust Fund and members of the proposed Class, against AstraZeneca LP, Aktiebolaget Hassle, AstraZeneca AB, Ranbaxy Pharmaceuticals, Inc., Ranbaxy Inc., Ranbaxy Laboratories Ltd., Teva Pharmaceutical Industries, Ltd., Teva USA, Inc., Dr. Reddy’s Laboratories Ltd., and Dr. Reddy’s Laboratories, Inc., alleging violations under Section 1 and 2 of the Sherman Act, 15 U.S.C. Sec. 1 and 2. Specifically, the Complaint alleges that AstraZeneca agreed to pay the Generic Defendants to defer entering the market until May 27, 2014 and to drop their challenges to the Nexium patents.
The Complaint seeks to represent a Class consisting of all consumers and third-party payors in the U.S. and Puerto Rico who purchased or paid for branded and/or generic Nexium products, other than for resale, since April 14, 2008.